A revolutionary blood test could soon predict not only an individual's risk of developing Alzheimer's disease but also the approximate year symptoms will begin.
Researchers at Washington University School of Medicine in St. Louis have identified a specific protein, p-tau217, in the blood that acts as a biological clock for the disease. This protein is linked to the formation of "tangles" in the brain that disrupt nerve cell communication, a hallmark of Alzheimer's.
Previously, brain scans were used to detect these tangles, but the process is often complex and expensive. This new study, published in Nature Medicine, analyzed data from over 600 older adults. It found that p-tau217 levels rise in a consistent pattern long before memory loss becomes apparent.
The research team developed a model that uses a patient's age and p-tau217 protein levels to estimate symptom onset with a margin of error of three to four years. "We show that a single blood test measuring p-tau217 can provide a rough estimate of when an individual is likely to develop symptoms of Alzheimer’s disease," stated lead author Kellen K. Petersen, PhD.
The study suggests that the speed at which symptoms manifest can be influenced by age and disease progression. While this advancement holds significant promise for clinical trials and identifying at-risk individuals, researchers caution that the test is not yet ready for widespread clinical use or personal medical decisions. "At this point, we do not recommend that any cognitively unimpaired individuals have any Alzheimer’s disease biomarker test," advised Dr. Suzanne Schindler, a neurologist involved in the study.
Future research aims to refine the test's accuracy by incorporating other Alzheimer's-linked proteins and expanding studies to more diverse populations. Two large clinical trials are currently underway to investigate whether early treatment with approved Alzheimer's drugs can benefit individuals with high protein levels before symptoms appear.